Deep Dive Into Hologic Stock: Analyst Perspectives (4 Ratings)


In the latest quarter, 4 analysts provided ratings for Hologic HOLX, showcasing a mix of bullish and bearish perspectives.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 0 1 0 0
Last 30D 1 0 0 0 0
1M Ago 2 0 1 0 0
2M Ago 0 0 0 0 0
3M Ago 0 0 0 0 0

The 12-month price targets, analyzed by analysts, offer insights with an average target of $88.25, a high estimate of $95.00, and a low estimate of $78.00. This current average reflects an increase of 13.14% from the previous average price target of $78.00.

Breaking Down Analyst Ratings: A Detailed Examination

In examining recent analyst actions, we gain insights into how financial experts perceive Hologic. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Mike Matson Needham Maintains Buy $90.00 -
Mike Matson Needham Maintains Buy $90.00 -
Vijay Kumar Evercore ISI Group Raises In-Line $78.00 $76.00
Patrick Donnelly Citigroup Raises Buy $95.00 $80.00

Key Insights:

  • Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hologic. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Hologic compared to the broader market.
  • Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Hologic's stock. This comparison reveals trends in analysts' expectations over time.

Capture valuable insights into Hologic's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Hologic analyst ratings.

Get to Know Hologic Better

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Financial Insights: Hologic

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Decline in Revenue: Over the 3 months period, Hologic faced challenges, resulting in a decline of approximately -5.69% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Hologic's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 24.33% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Hologic's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.1%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Hologic's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.8% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: Hologic's debt-to-equity ratio is below the industry average. With a ratio of 0.55, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

The Significance of Analyst Ratings Explained

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!